Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis...

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include; expert opinions on the modification of...

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include; the US Food and Drug Administration (FDA) approval of AstraZeneca’s...

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include; expert opinions on the 12-week Phase II study data published for Prometic’s PBI-4050 as a...

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned overall survival (OS)...

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and how this has...

Gain new KOL insights on the latest events happening in malignant melanoma (MM), including; data from Prima BioMed’s Phase I TACTI-mel clinical trial programme for IMP321, a first-in-class Antigen Presenting Cell...

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination with...